Periprocedural decrease in tumor necrosis factor alpha is a risk factor for atrial fibrillation recurrence after ablation

• Authors: Ewa Szczerba , Edward Koźluk , Łukasz Januszkiewicz , Monika Lisicka , Justyna Nowak , Agnieszka Kondracka , Joanna Majstrak , Dariusz Rodkiewicz , Agnieszka Piątkowska , Marek Kiliszek , Grzegorz Opolski

Abstracts

EN

Background
Concentration of tumor necrosis factor alpha (TNF-alpha) might be useful in selecting patients with paroxysmal atrial fibrillation (PAF) who will benefit the most from pulmonary vein isolation.
Material and methods
We performed prospective cohort study among patients with PAF who had sinus rhythm prior to undergoing either radiofrequency ablation or cryoablation procedure. Blood samples were collected at the start of the procedure and 16-24 h after. TNF-alpha concentrations were measured. Follow-up data was obtained during a structured telephone interview and 24-hour ECG Holter monitoring 12 months after the ablation procedure.
Results
Thirty seven patients were enrolled. After 12-month follow-up 27 patients maintained sinus rhythm, 8 had recurrence of AF and 2 were lost to follow-up. There was no significant correlation between TNF-alpha concentrations in any of the samples and the recurrence of arrhythmia (for pre-procedural samples: 1.75 pg/ml vs 1.74 pg/ml; p=0.72; for post-procedural samples: 1.49 pg/ml vs 1.79 pg/ml; p=0.16). In patients who had a recurrence of AF, we observed a decrease in the periprocedural TNF-alpha concentration (-0.12 pg/ml vs 0.05 pg/ml; p=0.05).
Conclusions
Neither pre- nor post-procedural TNF-alpha concentrations are predictive of ablation outcome in patients with PAF. We observed a decrease in the periprocedural TNF-alpha concentration in patients who had AF recurrence.

Keywords

EN

atrial fibrillation; ablation; TNF-alpha

• Publisher: Gdański Uniwersytet Medyczny
• Journal: European Journal of Translational and Clinical Medicine
• Year: 2022
• Volume: 5
• Issue: 2
• Pages: 16-23

Dates

published

2022

Contributors

author

Ewa Szczerba

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland
• Department of Cardiology, Institute of Mother and Child, Warsaw, Poland

author

Edward Koźluk

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland
• Department of Cardiology and Internal Medicine, Międzyleski Specialist Hospital, Warsaw, Poland

author

Łukasz Januszkiewicz

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland

author

Monika Lisicka

• Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland

author

Justyna Nowak

• Department of Internal Medicine, Endocrinology and Diabetology, Bródnowski Hospital, Warsaw, Poland

author

Agnieszka Kondracka

• Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Poland

author

Joanna Majstrak

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland

author

Dariusz Rodkiewicz

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland
• Department of Cardiology and Internal Medicine, Międzyleski Specialist Hospital, Warsaw, Poland

author

Agnieszka Piątkowska

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland
• Department and Clinic of Emergency Medicine, Wroclaw Medical University, Wroclaw, Poland

author

Marek Kiliszek

• Department of Cardiology and Internal Medicine, Military Institute of Medicine – National Research Institute, Warsaw, Poland

author

Grzegorz Opolski

• First Chair and Department of Cardiology, Medical University of Warsaw, Poland

References

• Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J [Internet]. 2021 Feb 1;42(5):373-498. Available from: https://doi.org/10.1093/eurheartj/ehaa612.
• Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J [Internet]. 2009;157(2):243-52. Available from: https://www.sciencedirect.com/science/article/pii/S0002870308008909.
• Guo Y, Lip GYH, Apostolakis S. Inflammation in Atrial Fibrillation. J Am Coll Cardiol [Internet]. 2012;60(22):2263-70. Available from: https://www.sciencedirect.com/science/article/pii/S0735109712044907.
• Yamashita T, Sekiguchi A, Iwasaki Y, Date T, Sagara K, Tanabe H, et al. Recruitment of Immune Cells Across Atrial Endocardium in Human Atrial Fibrillation. Circ J [Internet]. 2010;74(2):262-70. Available from: http://www.jstage.jst.go.jp/article/circj/74/2/74_CJ-09-0644/_article.
• Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol Circ Physiol [Internet]. 2005 Oct 1;289(4):H1456-67. Available from: https://doi.org/10.1152/ajpheart.00733.2004.
• Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, et al. Role of Tumor Necrosis Factor-α in the Pathogenesis of Atrial Fibrosis and Development of an Arrhythmogenic Substrate. Circ J [Internet]. 2013;77(5):1171-9. Available from: https://www.jstage.jst.go.jp/article/circj/77/5/77_CJ-12-1155/_article.
• Lee S-H, Chen Y-C, Chen Y-J, Chang S-L, Tai C-T, Wongcharoen W, et al. Tumor necrosis factor-α alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci [Internet]. 2007;80(19):1806-15. Available from: https://www.sciencedirect.com/science/article/pii/S0024320507001956.
• Wan S, Yim APC. Cytokines in myocardial injury: impact on cardiac surgical approach. Eur J Cardio-Thoracic Surg [Internet]. 1999 Sep 1;16(Supplement_1):S107-11. Available from: https://doi.org/10.1016/S1010-7940(99)00200-6.
• Burstein B, Nattel S. Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation. J Am Coll Cardiol [Internet]. 2008;51(8):802-9. Available from: https://www.sciencedirect.com/science/article/pii/S0735109707037862.
• Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial fibrillation: a maze of mechanisms. EP Eur [Internet]. 2012 Feb 1;14(2):159-74. Available from: https://doi.org/10.1093/europace/eur208.
• Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological Substrate of Atrial Biopsies in Patients With Lone Atrial Fibrillation. Circulation [Internet]. 1997 Aug 19;96(4):1180-4. Available from: https://doi.org/10.1161/01.CIR.96.4.1180.
• Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, et al. C-reactive Protein and Atrial Fibrillation Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J [Internet]. 2004;45(3):441-5. Available from: http://www.jstage.jst.go.jp/article/jhj/45/3/45_3_441/_article.
• Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of Multiple Inflammatory Biomarkers to Incident Atrial Fibrillation. Am J Cardiol [Internet]. 2009 Jul;104(1):92-6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002914909006808.
• Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a Risk Factor for Atrial Fibrillation. Circulation [Internet]. 2003 Dec 16;108(24):3006-10. Available from: https://doi.org/10.1161/01.CIR.0000103131.70301.4F.
• Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. Role of inflammation and oxidative stress in atrial fibrillation. Hear Rhythm [Internet]. 2010 Apr;7(4):438-44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1547527109013800.
• Aupperle H, Doll N, Walther T, Ullmann C, Schoon H-A, Wilhelm Mohr F. Histological findings induced by different energy sources in experimental atrial ablation in sheep. Interact Cardiovasc Thorac Surg [Internet]. 2005 Oct 1;4(5):450-5. Available from: https://doi.org/10.1510/icvts.2005.109413.
• Rafaqat S. Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology of Atrial Fibrillation. J Atr Fibrillation [Internet]. 2021 Aug 31;14(2). Available from: http://jafib.com/published.php?type=full&id=20200495.
• Wu N, Xu B, Xiang Y, Wu L, Zhang Y, Ma X, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol [Internet]. 2013 Oct;169(1):62-72. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167527313016616.
• Kimura T, Takatsuki S, Inagawa K, Katsumata Y, Nishiyama T, Nishiyama N, et al. Serum Inflammation Markers Predicting Successful Initial Catheter Ablation for Atrial Fibrillation. Hear Lung Circ [Internet]. 2014 Jul;23(7):636-43. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1443950614000730.
• Stavrakis S, Humphrey MB, Scherlag BJ, Hu Y, Jackman WM, Nakagawa H, et al. Low-Level Transcutaneous Electrical Vagus Nerve Stimulation Suppresses Atrial Fibrillation. J Am Coll Cardiol [Internet]. 2015;65(9):867-75. Available from: https://www.sciencedirect.com/science/article/pii/S0735109714075810.
• Çetin A, Çetin İ, Yılmaz S, Şen A, Savaş G, Çimen B, et al. Oxydative stress markers and cytokine levels in rosuvastatin-medicated hypercholesterolemia patients. 2019;44(4):530-8. Available from: https://doi.org/10.1515/tjb-2018-0267.

Identifiers

DOI

10.31373/ejtcm/156997

Biblioteka Nauki

25712809